Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) Director Bonnie L. Bassler sold 1,240 shares of the firm’s stock in a transaction on Friday, March 24th. The stock was sold at an average price of $818.00, for a total value of $1,014,320.00. Following the completion of the transaction, the director now owns 1,247 shares in the […]
Sequoia Financial Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 174.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,052 shares of the biopharmaceutical company’s stock after acquiring an additional 668 shares during the […]
Jefferies Financial Group upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) from a hold rating to a buy rating in a research report released on Friday morning, MarketBeat reports. Jefferies Financial Group currently has $925.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $675.00. Jefferies Financial Group also […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) had its price objective increased by BMO Capital Markets from $1,025.00 to $1,040.00 in a research note issued to investors on Friday morning, The Fly reports. A number of other analysts also recently issued reports on REGN. Barclays raised their target price on Regeneron Pharmaceuticals from $815.00 to $915.00 […]
Raymond James upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) from an underperform rating to a market perform rating in a research report released on Thursday morning, Marketbeat reports. Several other research analysts have also recently weighed in on the company. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $868.00 to $873.00 […]